At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 55 enrolled
Drug / intervention
Lebrikizumab Pendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Assess Lebrikizumab Pen Ease of Use in Patients With Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Lebrikizumab Pen for Atopic Dermatitis. Completed, enrolled 55 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose. Participants will complete the modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ) following the simulated injection. This study involves one study visit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
Enrollment StartJun 2024
First PostedJun 2024
Primary CompletionJun 2024
TodayJul 2026
First PostedJun 5, 2024
Enrollment StartJun 4, 2024
Primary CompletionJun 10, 2024
TodayJul 2, 2026
Enrollment to primary: 6 daysPosted 2.1 years ago
Interventions
Lebrikizumab Pendrug
Injected into a practice pad.